This year’s theme was “HEOR at the Nexus of Policy and Science” and, as with ISPOR in Boston in May, the real-world evidence (RWE) discussions largely focused on the use and acceptance of real-world data (RWD) in regulatory/reimbursement submissions.
The pressure on payers to offer patients timely access to life-saving oncology medicines has increased with the rapid development of innovative treatments. Balancing the urgency to provide access with the need for evidence-based decision-making from phase III trials presents a significant challenge to publicly funded systems worldwide.
The COVID-19 pandemic had profound impacts on healthcare systems and patients around the world. Systems faced unprecedented challenges including resource reallocation, overwhelmed hospitals, and disruptions in routine care. Retrospective studies are now assessing the long-term cumulative effects of the pandemic and associated public health measures.
The Table 2 fallacy suggests that even after carefully identifying confounding variables (covariates) to adjust for, it is common for researchers to mistakenly interpret each coefficient from an adjusted regression model as the total effect of the covariate, which is not the case.
Causal diagrams such as directed acyclic graphs (DAGs) can help in identifying a minimum set of confounding variables that need to be adjusted for. Arbitrarily dumping every available variable into a regression model can lead to biased estimates and incorrect conclusions about the effectiveness of a health intervention, its safety profile, and its downstream effects.
Medlior’s Founder and President Tara Cowling was delighted to attend the CADTH Symposium 2023 in Ottawa last week. On the heels of the ISPOR 2023 conference, CADTH also tackled some key issues surrounding the use of RWE to inform decision-making.
Hot-button items from the ISPOR 2023 conference included an emphasis on data quality, defining value, and caution with AI.
Treatment intensification and guideline LDL-C threshold achievement following acute myocardial infarction: Insights from a real-world evidence study
In a real-world Canadian population of high-risk patients with AMI, PCSK9i therapy in combination with other LLTs or alone was associated with better LDL-C reduction and higher proportions of patients meeting guideline thresholds; however, there was a longer time between the AMI event and PCSK9i treatments.
For many rare diseases, the drug development process is particularly challenging. A multi-pronged approach to overcoming these challenges is underway.
As we slowly emerged from our COVID caves of 2020-2021, this year brought great excitement to Medlior. We helped industry bring life-changing innovations to market, and we increased our stakeholder collaboration.